30
total announcements
RPGLIFE.NS · 15 min delayed
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about a scheduled Analyst/Institutional Investors meet on September 2, 2026, at 10:00 A.M. IST, which will be participated by the Company. The meet will be held in Mumbai/Physical mode.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed about the Schedule of Analyst/Institutional Investors Meet, which will be participated by the company. The details of the meet are as follows: Date: August 25, 2026, Time: 10.00 A.M. (IST), Venue: Antique Healthcare, Mumbai, Mode: Physical Group Meet, Nature of Meeting: Investor Conference.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about the Resignation of Director/KMP/SMP, but no further details are provided.
RPG Life Sciences Limited
RPG Life Sciences Limited has announced the resignation of Mr. Deepak Shukla, Chief Executive - API Business, effective August 14, 2026, due to his appointment as Chief Executive Officer of RPG Active Pharma Limited, a wholly-owned subsidiary.
RPG Life Sciences Limited
RPG Life Sciences Limited has completed the transfer of its Active Pharmaceuticals Ingredients (API) business to RPG Active Pharma Limited, a wholly owned subsidiary, effective from August 15, 2026.
RPG Life Sciences Limited
RPG Life Sciences Limited has made an investment of up to Rs.65,68,60,500 in the Rights Issue of equity shares of RPG Active Pharma Limited, a wholly owned subsidiary.
RPG Life Sciences Limited
RPG Life Sciences Limited has announced an Analyst/Institutional Investors meet on August 13, 2026, at Emkay Confluence in Mumbai.
RPG Life Sciences Limited
RPG Life Sciences Limited has announced the superannuation of Mr. Samir Rane, Vice President, Sales & Marketing - Main Division, effective July 31, 2026. The company has disclosed the required information as per SEBI Listing Regulations.
RPG Life Sciences Limited
RPG Life Sciences Limited has announced a special window for the lodgment of transfer and dematerialization requests for physical securities sold or purchased prior to April 1, 2019. The company has also announced an Extra Ordinary General Meeting (EOGM) to be held on a specified date.
RPG Life Sciences Limited
RPG Life Sciences Limited has announced a strategic API initiative to accelerate its next phase of growth. The company has executed an agreement to transfer its API business to its wholly owned subsidiary, RPG Active Pharma Limited, and will raise an initial amount of up to INR 243 crore from funds managed by Inv Ascent. RPG Active Pharma will also acquire 100% equity share capital of Actis Generics Private Limited.
RPG Life Sciences Limited
RPG Life Sciences Limited has announced the execution of a Business Transfer Agreement for the sale of its Active Pharmaceutical Ingredients (API) business to its wholly-owned subsidiary, RPG Active Pharma Limited, for a consideration of Rs. 33.55 crore. The sale is expected to be completed by September 30, 2026, subject to customary conditions.
RPG Life Sciences Limited
RPG Life Sciences Limited has executed a Business Transfer Agreement for the sale of its Active Pharmaceutical Ingredients (API) business to RPG Active Pharma Limited, a wholly-owned subsidiary, for Rs. 33.55 crore. The sale is expected to be completed by September 30, 2026. The transaction is a related-party transaction done at arm's length and is outside the Scheme of Arrangement.
RPG Life Sciences Limited
RPG Life Sciences Limited has announced the outcome of its Board Meeting held on July 29, 2026, where it considered and approved the execution of Business Transfer Agreement for the sale of its Active Pharmaceutical Ingredients (API) business to RPG Active Pharma Limited, a wholly owned subsidiary. The sale is expected to be completed on or before September 30, 2026.
RPG Life Sciences Limited
RPG Life Sciences Limited has published unaudited financial results for the quarter ended June 30, 2026, in accordance with SEBI regulations. The results are available on the company's website and in newspapers.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about Investor Presentation with respect to Unaudited Financial Results for the quarter ended June 30, 2026.
RPG Life Sciences Limited
RPG Life Sciences Limited has announced its financial results for Q1 FY27, with revenue growing 15.8% to ₹195.7 crore and EBITDA growing 17.9% to ₹48.0 crore, with EBITDA margin improving to 24.5%. The company's Domestic Formulations business delivered 14.8% growth, outperforming the Indian Pharma Market growth of 11.6%. The company has also entered the Top 50 Indian pharmaceutical companies list.
RPG Life Sciences Limited
RPG Life Sciences Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 19,569 lakhs and total income at Rs. 19,985 lakhs.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about the resignation of a Director/KMP/SMP.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange regarding the cessation of Ms. Zahabiya Khorakiwala as an Independent Director of the company, effective July 26, 2026, due to the completion of her second consecutive five-year term.